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Abstract
Background: The increasing number of known protein structures provides valuable information
about pharmaceutical targets. Drug binding sites are identifiable and suitable lead compounds can
be proposed. The flexibility of ligands is a critical point for the selection of potential drugs. Since
computed 3D structures of millions of compounds are available, the knowledge of their binding
conformations would be a great benefit for the development of efficient screening methods.
Results:  Integration of two public databases allowed superposition of conformers for 193
approved drugs with 5507 crystallised target-bound counterparts. The generation of 9600 drug
conformers using an atomic force field was carried out to obtain an optimal coverage of the
conformational space.
Bioactive conformations are best described by a conformational ensemble: half of all drugs exhibit
multiple active states, distributed over the entire range of the reachable energy and conformational
space.
A number of up to 100 conformers per drug enabled us to reproduce the bound states within a
similarity threshold of 1.0 Å in 70% of all cases. This fraction rises to about 90% for smaller or
average sized drugs.
Conclusion: Single drugs adopt multiple bioactive conformations if they interact with different
target proteins. Due to the structural diversity of binding sites they adopt conformations that are
distributed over a broad conformational space and wide energy range. Since the majority of drugs
is well represented by a predefined low number of conformers (up to 100) this procedure is a
valuable method to compare compounds by three-dimensional features or for fast similarity
searches starting with pharmacophores.
The underlying 9600 generated drug conformers are downloadable from the Super Drug Web site 
[1]. All superpositions are visualised at the same source. Additional conformers (110,000) of 2400 
classified WHO-drugs are also available.
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Background
Most approaches for drug discovery start with the identifi-
cation of a target which plays an important role in the pro-
tein interaction network of a particular disease. Proposals
of novel ligands which inhibit such targets are a great chal-
lenge for drug design [2]. Fortunately, the increasing
number of known 3D protein structures provides promis-
ing information for structure based interaction models.
Based on the assumption that successful leads exhibit geo-
metric and chemical complementarity with their binding
sites, a pharmacophore is often specified that represents
the ligand of the enzyme's active site by three-dimen-
sional features [3-5]. In a second step either large con-
former databases of known compounds are searched for
suitable candidates [6,7] or new compounds are modelled
which are compatible with the phamacophore [8].
Selected or modelled leads are subject to experimental
screening.
Modelling drug-target complexes originating from the
unbound lead structures entails some difficulties. Since
structural changes upon ligand binding may occur, the
flexibility of both the binding site as well as the ligand has
to be considered by simulated docking. Molecular move-
ments upon binding are described for protein-protein
interactions [9], protein-DNA interactions [10] as well as
the interaction of proteins with small compounds
[11,12]. All of these reports emphasise that often large
side-chain movements are observed upon molecular
interaction. This is best described by the induced fit model
introduced by Koshland [13].
Similarly, the conformational change of drug-like com-
pounds upon binding may be difficult to calculate when
the bound conformation is unknown. Changes in only a
few rotatable bonds may cause an enormous number of
possible conformations.
However, current docking applications like FlexXs (Tripos
Inc.), FRED (OpenEye Scientific Software), Glide
(Schrödinger Inc.) and Gold (CCDC) generate a number
of conformers in vacuum or a continuum solvent which
are distributed over the energetically accessible conforma-
tional space. If they are suitable for the predetermined
binding site, all generated conformers come into consid-
eration for further adjustments. At present this procedure
is an effective method to model the bound conformation
of ligands in complex with their target proteins.
Different programs are available to generate preferably
few conformations combined with a good coverage of the
conformational space, e.g. Catalyst (Accelrys), ICM (Mol-
soft LLC), Omega (OpenEye) and CORINA (Molecular
Networks GmbH).
To identify available compounds with the desired effect
on a given protein, millions of tradable compounds come
into question. Although virtual screening methods may
shorten expensive laboratory tests and gain importance
over random experimental screening [14], they can be
very time-consuming. If 3D features and flexibility of
drugs are taken into account, all reachable conformations
of each drug have to be considered.
The present work aims in an acceleration of 3D-screening
methods. In order to do this we raise the question how
well a bound drug is represented by a limited number of
computed conformers and how many conformers are nec-
essary to achieve a good representation. Furthermore, we
investigate whether particular features of bound ligands
exist which might be helpful to restrict the conforma-
tional space that has to be examined.
Results
Drug characteristics
Regarding size, rotatable bonds and number of rings, the
193 analysed drugs are not uniformly distributed. Small
compounds are more frequently present than larger mol-
ecules (Fig. 1a). This tendency is more distinctive if the
number of rotatable bonds is taken into account (Fig. 1b).
Obviously, many larger drugs contain rings which prevent
free rotation of single bonds. Two thirds of the drugs orig-
inated from the PDB contain 0–5 rotatable bonds. Drugs
having more than 10 rotatable bonds are represented by a
small fraction (14%). The 193 compounds contain 22.69
heavy atoms and 5.58 rotatable bonds on average.
Assignment of bound conformations to generated free 
conformers
Each bound conformation was superimposed with the
most similar generated unbound state. Fig. 2a illustrates
the best assignments if maximal 100 generated conform-
ers per drug are taken into account. Each point represents
the average rmsd of the occuring bound instances per
drug, with every bound ligand instance assigned to the
most similar computed conformer. 70% of the 193 drugs
are represented by a generated conformer with a rmsd
lower than 1 Å. With up to 5 rotatable bonds 93% (61%)
of the rmsd-values fall below 1 Å (0.5 Å).
A limitation to those conformers with lowest energy (30%
of maximal 100 computed conformers) is shown in Fig.
2b. Compared to figure 3a, a conspicuous shift from low
deviations (0–0.5 Å) to higher deviations (0.5 Å-1 Å) is
present. Furthermore, some bound drugs with many
rotatable bonds (>15) are worse represented by a gener-
ated conformer.
An assignment of all bound ligands to maximal 10 instead
of 100 generated drug conformers per drug yields toBMC Bioinformatics 2006, 7:293 http://www.biomedcentral.com/1471-2105/7/293
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higher deviations and more flexible drugs are more
affected than smaller molecules (Fig. 2c). 61% of all ana-
lysed drugs are still represented by conformers with an
average deviation less than 1 Å. This fraction rises to 86%
for average sized or smaller drugs, if an average size of 5.6
rotatable bonds is assumed, specified by Feher et al. [15].
The lowest rmsd-values are achieved if only drugs are con-
sidered that follow the Lipinski's "rule of five" [16] (Fig.
2d). The main cause is the absence of molecules that are
highly flexible (rotatable bonds > 18) – these molecules
are difficult to reproduce by a limited set of conformers.
Furthermore, they are less applicable for medical com-
pounds than smaller molecules because of weak mem-
brane permeability [16]. 79% of the 165 drugs of the
subset are represented by computed conformers with a
deviation less than 1 Å.
Bioactive conformations
Due to the fact that single drugs interact with various pro-
teins, the effect on ligand conformation has to be consid-
ered. 46% of the 193 inspected drugs are assigned to more
than one computed conformer indicating multiple bioac-
tive states. Exemplarily we have analysed one drug in
detail (Methotrexate, Fig. 3) that is flexible (10 rotatable
bonds), occurs frequently within the dataset (42 times)
and interacts with different target proteins. Fig. 4 shows
the correlation between sequence similarity of the pro-
teins and conformation of the bound ligands. The diago-
nal axis from the upper right to the lower left side divides
the sequence similarity scores of the proteins and the
rmsd-values of Methotrexate ligands when each sequence/
conformer is compared to each other. The resulting align-
ment scores are clustered and translated into associated
colours. The rmsd values of the superposed ligands are
shown in the associated order of the sequences and are
coloured in an analogous manner.
While seven distinct groups of sequences are observable,
the bound ligands are divided into four distinct groups.
27 of the 42 protein chains possess an identical sequence
and are clustered together within the lower left quarter.
The corresponding bound ligands are highly similar but
exhibit small deviations. Similar proteins indicated by a
high sequence similarity score are mostly associated with
similar drug conformations. The only exception is the
homodimer of the crystal structure 1AXW (thymidylate
synthase from Escherichia coli). Two distinct drug confor-
mations are bound to sequence-identical chains.
The structural diversity of the ligands is lower than the
diversity of the sequences but at least four differentiated
groups are observable. One of those groups contains an
above-average number of instances that are distributed
Drug distribution per heavy atoms Figure 1
Drug distribution per heavy atoms. a) Histogram of 193 analysed drugs ordered by number of heavy atoms. b) Histogram 
of 193 analysed drugs ordered by number of rotatable bonds.BMC Bioinformatics 2006, 7:293 http://www.biomedcentral.com/1471-2105/7/293
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over five different protein sequences. Apparently this con-
formation is favoured over the other three occurring dis-
tinct conformations. However, clear spatial differences
between all bound drug instances are present that vary
from 0.08 Å to 3.23 Å. Obviously the bioactive conforma-
tions are distributed over a wide spatial range.
Drug-Ligand assignments Figure 2
Drug-Ligand assignments. Each point represents one drug and indicates the average rmsd between bound instances and 
assigned unbound conformers. The vertical reference line (rb avg*) indicates the average number of rotatable bonds specified 
by Feher et al. [15]. a) Maximal 100 generated conformers per drugs were considered for drug ligand assignment. b) Drugs are 
assigned to low strain energy conformers. 30% of maximal 100 generated conformers were considered. c) Maximal 10 gener-
ated conformers per drugs were considered for drug ligand assignment. d) Maximal 100 generated conformers per drugs were 
considered and drugs violating Lipinski's "rule of five" were excluded.BMC Bioinformatics 2006, 7:293 http://www.biomedcentral.com/1471-2105/7/293
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This tendency is also visible if the energy distribution is
taken into account. No tendency to high or low energies
was detected within the dataset containing 9600 drug
instances (data not shown). Rather the energies of ligand-
assigned conformers cover the entire range of computed
strain energies.
Beside energy, the radius of gyration was considered for
detection of spatial characteristics that could discriminate
bound and unbound drug conformations. Compared to
the computed ensemble of conformers, isolated bound
drugs that are represented by few instances exhibit out-
standing low and high gyrations respectively (data not
shown). Nevertheless the inclusion of all bound instances
indicates that the average radii of bound and generated
unbound conformers are highly similar.
Discussion
Apparently, binding sites originated from various differ-
ent proteins induce ligand conformations which are often
deviating from each other. A recent analysis of the struc-
tural diversity of ATP, NAD and FAD points out a correla-
tion between sequence similarity and conformation of the
ubiquitous ligands [17]. Since these ligands interact with
many different proteins a large number of distinct confor-
mations was found. The presence of many bioactive con-
formations per drug shows that a set of conformers or a
flexible drug model is required to represent the bound
drug adequately. At present, flexible docking methods by
means of MD-simulations are time-consuming and
expensive [18].
Other methods allow flexible superpositions of small
molecules but recent algorithms suitable for fast screening
methods require a set of rigid conformers for further flex-
ible refinements [19]. Thus a representation of each mol-
ecule by a limited set of conformers is a reasonable
approach for 3D screening methods.
We proved in which way the offered drug conformers
available in the SuperDrug Database reflect the protein-
bound structure. The distribution of the analysed 193
drugs corresponds to a much larger data collection based
on 11000 compounds extracted from various large medi-
cal compound libraries [15]. The authors determined an
average drug size of 23.5 heavy atoms (here: 22.69) and
5.6 rotatable bonds (here: 5.58).
The deviations between computed conformers and bound
ligands mainly depend on the method of conformer gen-
eration. Beside other factors modelling within vacuum as
well as in solvent comes into question. Perola and Char-
ifson analysed in detail the spatial similarity of generated
conformers with their target bound counterparts on a
Methotrexate bound to different proteins Figure 3
Methotrexate bound to different proteins. Three different proteins are shown in cartoon representation. The bound 
conformations of Methotrexate (coloured dark blue) is shown in stick representation. The lower figures show the bound con-
formations originating from crystal structure (left hand site) and most similar computed drug conformer (right hand site). a) 
Thymidilate synthase of Escherichia coli (PDB: 1AXW, chain A). b) Dihydrofolate reductase of Homo sapiens (PDB: 1DLS). c) 
Pteridine Reductase 2 from Trypanosoma cruzi (PDB: 1MXF, chain D)BMC Bioinformatics 2006, 7:293 http://www.biomedcentral.com/1471-2105/7/293
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Sequence similarity compared to spatial similarity of bound ligands Figure 4
Sequence similarity compared to spatial similarity of bound ligands. The upper left site represents the sequence sim-
ilarity of Methotrexate binding proteins. The lower right represents the rmsd-values of associated ligand superpositions. See 
text for further information.BMC Bioinformatics 2006, 7:293 http://www.biomedcentral.com/1471-2105/7/293
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smaller set of protein-ligand complexes and considered
the generation of the conformers in vacuum as well as in
solvent [20]. Although the obtained conformers of both
methods exhibit significant spatial differences, the differ-
ent methods result in similar deviation levels between
bound and generated states. Therefore it is assumed that
conformer generation in vacuum is a convenient method
even if the obtained conformers may differ from those
generated in solution.
Different features were analysed which might be helpful
to minimise the number of computed conformers that
have to be considered for a suitable representation of all
occurring bound conformations.
A potential classifier might be the strain energy. If the
number of used conformers is reduced to conformers with
low strain energy the obtained deviations are conspicu-
ously increased. This fact is explainable by an undersized
spatial coverage: Since bioactive conformations are dis-
tributed over the whole reachable energy and conforma-
tion space, all conformers have to be considered to
prevent an inadequate coverage. This aspect is discussed
ambiguously by existing evaluations. A study comprising
27 protein-ligand complexes specifies the strain energy
range of the bound ligands from 0 to 39.7 kcal/mol, with
an average of 15.9 kcal/mol [21]. The strain energy
appeared to be proportional to the number of rotatable
bonds. Bostrom et al. [22] selected 33 protein-ligand com-
plexes from the PDB and calculated the strain energy for
each ligand. The authors suggest that 3 kcal/mol could be
used as a general threshold. In the third study, performed
on a set of 10 complexes, a strain energy range from 0 to
9 kcal/mol was calculated [23]. Little similarity between
low energy solution conformers and the crystallographic
conformers was found if the complete molecule is taken
for superposition. However, similar positions were found
if the comparison is restricted to atoms which are respon-
sible for tight binding ('anchor points'). In the most
recent work 150 crystal structures were analysed [20].
Approximately 60% of the drug-like compounds were cal-
culated to bind with strain energies lower than 5 kcal/mol,
while 10% exceeded 9 kcal/mol.
The four reports specify diverse energy values of bound
ligands, but none of them describes a clear tendency to
low or high strain energies of bound ligands. Here we
used the default energy cutoff value of Catalyst (20 kcal/
mol) to cover most of all occurring strain energies without
oversizing the resulting conformational space.
The energy surface of the individual molecule in solution
is complex because interacting with the solvent allows
switching through a large number of conformations
located in various local energy minima.
Especially in the case of a missing binding site structure
the inclusion of the strain energy for prediction of active
conformations would be useful if bound drugs occupy
predominantly low energy states within a given strain
energy interval. Since that tendency does not exist, this
feature is of low value for prediction methods. Drug con-
formations that exhibit higher energies are in fact stabi-
lised by the interaction with the protein.
Hence, the inclusion of a known drug binding site for 3-D
screening methods is a meaningful method. For instance
the knowledge of the locations of the H-bond acceptors/
donors could be used to select potential bioactive confor-
mations of the ligand.
A larger fraction of well represented drugs is achieved if
only those drugs are taken into account that follow the
Lipinski's "rule of five". Most drugs that break the rule are
large and highly flexible and therefore exhibit a weak
membrane permeability [16]. The bound states of 79% of
the remaining 165 drugs are represented by a conformer
with an average deviation lower 1 Å. For fast high
throughput screenings (HTS) it might be sufficient to
reduce the number of generated conformers to maximal
10. This procedure is recommended if average sized or
smaller drugs shall be represented. Up to an average drug
size of 5.6 rotatable bonds 86% of the 131 drugs possess
rmsd-values lower 1 Å.
Consequently, the deviation between bound state and
unbound model increases with rising number of rotatable
bonds. Larger molecules containing more than 10 rotata-
ble bonds are approximated by considerably higher rmsd
values than 1 Å, even if maximal 100 conformers are gen-
erated. Although a higher amount of computed conform-
ers would result in better spatial coverage, it has to be
considered that the number of rotatable bonds correlates
exponentially with the number of reachable conforma-
tions. Highly flexible compounds are much more expen-
sive to represent than more rigid molecules. Furthermore,
a large number of conformers is unsuitable for fast HTS-
methods. However, even a relative small ensemble of
large computed molecules provides a basis for further
refinements by docking simulations that incorporate the
target binding site.
The radius of gyration was also considered as a feature to
restrict the energetically accessible conformational space
of bound compounds. This approach is based on the sim-
ple assumption that a high binding affinity requires a
large buried surface area of the protein that is achieved by
an enlarged bound ligand.
Though such an assumption may explain individual cases
of outstanding high gyrations, it is expected that the vari-BMC Bioinformatics 2006, 7:293 http://www.biomedcentral.com/1471-2105/7/293
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ous different mechanisms and geometric features of pro-
tein ligand interactions require an individual inspection
of the conformational change upon binding. However,
comparisons of all analysed drugs did not result in a ten-
dency to high radii of gyrations of bound conformers.
Since not only large side chain movements of binding site
residues but also reformations of the entire protein back-
bones are observable upon ligand binding [24], many dif-
ferent geometric and electrostatic factors come into
question to explain the forming of the drug's bound con-
formation. Furthermore, thermodynamic analysis could
show that binding affinity does not necessarily correlate
with the buried surface area of the protein [25].
A substantial progress for currently available docking
tools is the determination of the compounds' binding
affinity in a modelled drug target complex. The binding
affinity depends on the intramolecular and intermolecu-
lar interactions and dynamics of the system components,
including the protein, the ligand, water and any addi-
tional components that may be present. All occurring
energetic differences between bound and unbound states
are reflected by the reaction enthalpy and entropic effects,
but especially the contribution of the latter is very difficult
to estimate [26], although approximations have been suc-
cessful recently [27,28].
Promising methods to estimate the binding affinity are
free-energy perturbation (FEP) calculations. Such
approaches exploit the fact that many important proper-
ties depend on local changes in the macromolecules so
that the effect of the overall macromolecular potential
cancels out. Although such calculations require extensive
computational effort a recent study could show that this
method is also applicable for ligand screening [29].
However, geometric and electrostatic complementarity
are fundamental attributes for molecular docking. There-
fore it is meaningful to describe medical compounds by
three-dimensional features. If those parameters are used
for screening of large compound libraries fast comparison
methods are required. Here we arrive at the conclusion
that a representation of each compound by a certain
number of maximal 100 conformers is a meaningful
approach for high throughput in silico screening. For
average or smaller sized drugs (rotatable bonds < 6) a
number of up to 10 conformers is sufficient to represent
the bound states adequately.
Conclusion
The bound conformations of average sized or smaller
drugs are well represented by a set of up to 10 conformers
which were computed to obtain an optimal coverage of
the conformational space. Compared to generated con-
formers the drugs' bound states exhibit neither outstand-
ing energies nor enlarged radii of gyrations. In fact, single
drugs exhibit multiple bioactive conformations if they
interact with different target proteins. Due to the struc-
tural diversity of binding sites they adopt conformations
that are distributed over a broad conformational space
and wide energy range. Since drugs are representable by a
predefined low number of conformers this procedure is a
useful way to compare compounds by three-dimensional
features or for fast similarity searches starting with phar-
macophores.
Methods
Selection of drugs and representing conformers
The selection of the drugs arises from the intersection set
of two different databases: the drug has to be recorded in
the SuperDrug database [30], as well as the SuperLigands
database [31].
The first is a publicly accessible source of structures of
approved drugs. It contains about 2500 3D-structures of
active ingredients of essential marketed drugs. To account
for structural flexibility these drugs are represented by 105
structural conformers. For selection purposes or for corre-
lation of structural similarity with medical application,
the assignment of the Anatomical Therapeutic Chemical
(ATC) classification codes to each structure according to
the WHO-scheme is provided. A web-query system ena-
bles searches for drug name, synonyms, trade name, triv-
ial name, formula, CAS-number, ATC-code and 2D-
similarity screening (Tanimoto coefficients). Further-
more, an automatic 3D-superposition procedure based on
conformational representation is implemented.
SuperLigands supplements the set of existing resources of
information about small molecules occurring in the PDB
[32]. It is an Internet accessible database delivering such
PDB ligands in their bound conformations in the MDL
Mol file format. Currently, SuperLigands comprises over
70,000 experimentally determined three-dimensional
structures of more than 5,000 different low molecular
weight compounds. Information like name, molecular
formula or PDB identifier, atom numbers and occurrence
in the PDB can be obtained. Structural similarity of the
compounds can be detected by calculation of Tanimoto
coefficients and by three-dimensional superposition. Top-
ological similarity of PDB ligands with known drugs can
be assessed via Tanimoto coefficients.
The PDB compounds analysed in this work must satisfy
the following additional criteria:
non-covalent binding between drug and protein; struc-
tures have to be determined by X-ray crystallography; theBMC Bioinformatics 2006, 7:293 http://www.biomedcentral.com/1471-2105/7/293
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drug consists of at least 6 heavy atoms; the drug is speci-
fied completely.
The resultant dataset consists of 193 diverse drugs, 1911
different PDB-files and 5507 drug-target instances. The
generated unbound drugs are represented by 9600 con-
formers in total. A complete list of all used PDB-ID's, HET-
ID's, name of drugs and CAS-numbers is published at the
Super Drug Web site [1]. The generated unbound con-
formers used for superpositions, the bound ligands as
well as the visualised superpositions, are publicly availa-
ble at the same source (Fig. 5).
Unbound conformational ensemble
Selected conformers were generated in vacuum with Cata-
lyst v4.7 (Accelrys) – a modified version of the CHARMm
force field [33] – using BEST model. The program uses a
poling algorithm to maximise diversity [34] and to
improve the coverage of conformational space [35,36].
Similar conformers within a distance tolerance are elimi-
nated to reduce the resulting number of conformers. The
RMS tolerance is computed as:
RMS_TOL = 0.1 + C * sqrt (1 + Nrot)
where C is a scaling constant and Nrot is the number of
rotatable single bonds. The default value of 20 kcal/mol
was used as the relative maximum energy and C was set to
0.11. The adjustable maximum number of computed con-
formers per compound was set to 10 and 100 respectively.
If a fewer number of conformers is sufficient to cover the
Website Figure 5
Website. Screenshot of the website providing supporting information [1].BMC Bioinformatics 2006, 7:293 http://www.biomedcentral.com/1471-2105/7/293
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conformational space, dependent on C, those drugs are
represented by a minor ensemble.
For the calculation of the energy Catalyst uses a modified
version of the CHARMm force-field. The energy is
described as sum of the energies due to various interac-
tions within the molecule. The implementation contains
the energy terms bond stretching, angle bending, linear
deformation, out-of-plane deformation, dihedral torsion
and van der Waals interactions.
The strain energy is defined by the energy that is released/
absorbed when the conformation of a molecule changes.
It is measured relative to the global energy minimum
whose strain energy is zero.
Assignment of bound structures to generated conformers
All bound conformations originated from the PDB were
assigned to the most similar spatial conformer of the same
drug. Specified measurement was the root mean square
deviation (rmsd). Pairwise assigned atoms had to be of
the same element and at the same position within each
molecule. If symmetric molecules allow an alternative
superposition, the variant having the lowest deviation was
selected. To obtain the maximal occurring deviations no
rmsd cutoff was defined. The rmsd plots contain a dashed
line at 1 Å for a better comparability.
The crystallographic conformation of bound ligands is
based on an approximation derived from experimental
electron density and contains significant uncertainties.
The approximated atom positions are refined by a force
field. Since different force fields have different optimal
values for bond lengths and angles, small adjustments of
the parameters may result in an artificially large energy
change. Direct measurement of the strain energy of the
bound ligands would require normalised bond length
and angles that correspond to the force field parameters
used for measurement. Therefore the strain energy calcu-
lations performed here do not refer to the chrystallo-
graphically determined conformation but to the most
similar computed conformer.
For each compound the number of heavy atoms and
rotatable bonds were calculated with DS-Viewer (Accel-
rys) and the radius of gyration was calculated with PyMOL
(DeLano Scientific). As most of the molecules published
in the PDB do not contain hydrogen atoms these atoms
were ignored in conformer superpositions. The number of
rotatable bonds was calculated without freely rotatable
terminating groups (such as CH3, NH3, OH, etc.). This
procedure takes into account the missing hydrogen atoms
and should reflect the flexibility of the molecular scaffold.
The number of broken Lipinski rules per drug was calcu-
lated with Accord (Accelrys).
Sequence alignments
The similarity map shown in Fig. 4 was generated with the
R-package and is based on a multiple sequence alignment
followed by a pairwise determination of similarity. This
procedure is an integrated function within the alignment
tool STRAP [37].
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